USA flag logo/image

An Official Website of the United States Government

Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93982
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HL097521
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VASCULOX, INC.
4320 Forest Park Avenue Suite 303 SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Treatment of Transplant Reperfusion with an Anti-CD47 Antibody
Agency: HHS
Contract: 1R43HL097521-01
Award Amount: $203,191.00
 

Abstract:

DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs and tissues for transplant in attempts to increase the supply of donor organs acceptable for transplantation. A key goal of preconditioning is to reduce the damage inflicted by ischemia-reperfusion injury (IRI) t hat occurs when the ischemic/ hypoxic organ is connected to the recipient's circulation. This storm of reactive oxygen species, inflammatory mediators and prothombotic factors threatens to kill the new organ and wreaks havoc upon the recipient as well. Cur rent work indicates that enhancing the low levels of nitric oxide (NO) produced by eNOS and nNOS can dramatically improve IRI and transplant outcomes. The founders of Vasculox, Inc have discovered a receptor, CD47, that continually opposes the action of be neficial NO in all vascular cells. Knocking out CD47 in mice or blocking CD47 with a monoclonal antibody (mAb) results in enhanced tissue perfusion in a number of surgical ischemia models and protection from IRI in both liver and hindlimb models. In this p hase one proposal, we seek to perform proof of concept studies in a well-characterized rat model of liver transplantation, testing the efficacy of anti-CD47 mAb treatment of the donor liver to protect it from IRI. Here we will compare the best case scenari o in which anti-CD47 mAb is administered to the donor rat and maintained throughout liver harvest, cold storage and reperfusion, with the worst case of no CD47 blockade. In our protocol, the heart-beating donor rat will be treated with anti-CD47 mAb, the l iver harvested and flushed with anti-CD47 mAb, subjected to cold storage ischemia and then rewarmed in the presence of mAb under controlled conditions of machine reperfusion. After a fixed interval of reperfusion, levels of released soluble liver enzymes a nd inflammatory mediators will be assayed, tissue taken for assays of ATP and cyclic nucleotides and the liver fixed for quantitative cytologic analysis and histochemical staining for the distribution of the anti-CD47 mAb and apoptosis (TUNEL and cleaved c aspase). A simplified nonheart-beating donor model will also be performed when a period of warm ischemia is interposed between mAb administration and organ harvest. The data obtained in this phase I project will establish proof of concept for anti-CD47 mAb therapy in this liver transplant model. Phase II will address the real world situation of transplantation of treated or control livers into living recipients that can then be treated (or not) with the anti-CD47 mAb. While we have chosen to focus here on the liver model, we anticipate that anti-CD47 therapy will be of benefit in the transplantation of other organs (heart, kidney, lung, etc) as well as in surgeries involving organ resection for trauma and cancer and, potentially, in myocardial infarction a nd stroke. PUBLIC HEALTH RELEVANCE: The founders of Vasculox Inc, have discovered a regulatory receptor, CD47, that inhibits nitric oxide signaling in all vascular tissues. Nitric oxide provides many beneficial effects in the vascular system, including lim iting ischemia-reperfusion injury. Therefore blocking CD47 and removing nitric oxide inhibition improves ischemia-reperfusion injury and holds promise as a means to improve the condition of organs destined for transplant and to control the damage to the re cipient caused by ischemia reperfusion injury. Vasculox is developing a monoclonal antibody that targets CD47 and in this project aims to test the efficacy of such an antibody in a rat model of organ harvest, transport and reperfusion.

Principal Investigator:

Pamela A. Toymanning
PAM@VASCULOX.COM

Business Contact:

Robert W. Kurxu
Small Business Information at Submission:

VASCULOX, INC.
9256 LITZSINGER ROAD SAINT LOUIS, MO 63144

EIN/Tax ID: 126201281
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No